Versant Venture Capital IV, L.P.

Versant Venture Capital IV, L.P. is a declared insider at 3 companies; the most frequent names are CRISPR Therapeutics AG, IVERIC bio, Inc. and Clovis Oncology, Inc. Over a trading history stretching from 16 November 2011 to 19 June 2020, the count stands at 52 filings.

The open-market side counts 6 purchases for €2.1M alongside 4 sales for €4.2M. No amount is published for 2 filings, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 4 share grants.

In size, the median ticket on the buying side is €417k.

Most recently, on 23 June 2020, the filings show a transaction in IVERIC bio, Inc. The last insider purchase was made public on 23 December 2016, 3,608 days ago. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.